ClinicalTrials.gg
RecruitingNCT07439575Updated Mar 2, 2026

Wound Closure Materials and Techniques in Hip and Knee Arthroplasty

An interventional study of Barbed Suture Wound Closure and Conventional Suture Wound Closure in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Bahattin Kemah. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Bahattin Kemah · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2025, registered Feb 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Osteoarthritis, Knee with a site in Turkey — 52 open to participants now, 63 under way, 3 of them phase 3. Osteoarthritis, Knee · Turkey.

Planned enrollment
32nd of 198
90 · median 60
Started
2025
with 46 others
No phase
189 of 268
30 open now
Primary completion
2026-08
later than 23 of 62 live
Registered
225th of 268
by date

Among the 268 studies in Osteoarthritis, Knee with a site in Turkey, this one is the 32nd largest by planned enrollment of the 198 interventional ones that give a count, is one of 47 that started in 2025, is one of 189 with no phase, reaches primary completion later than 23 of the 62 other live ones, and was the 225th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

52 of the 268 studies in Osteoarthritis, Knee with a site in Turkey are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Osteoarthritis, Knee with a site in Turkey, or all of them as a file.
02

Study summary

This prospective randomized clinical study aims to evaluate the effects of different suture materials and wound closure techniques on wound healing, functional outcomes, and postoperative complications in patients undergoing total hip and knee arthroplasty.

A total of at least 90 adult patients undergoing primary or aseptic revision lower extremity arthroplasty will be randomized into two groups according to the wound closure material and technique used. All surgeries will be performed by the same surgical team following standardized operative protocols.

Primary outcomes include wound-related complications such as prolonged wound drainage, wound dehiscence, surgical site infection, and local inflammatory findings within 90 days postoperatively. Secondary outcomes include operative time, bleeding amount, cosmetic outcomes, and functional scores.

The results of this study are expected to help determine the most effective and safe wound closure method in lower extremity arthroplasty.

Read the detailed description

Total hip and knee arthroplasty are commonly performed surgical procedures in the management of end-stage degenerative joint diseases. Optimal wound closure is critical in reducing postoperative complications such as prolonged wound drainage, wound dehiscence, surgical site infection, and delayed wound healing. Various suture materials and closure techniques are routinely used in clinical practice; however, consensus regarding the most effective method remains limited.

This prospective randomized study is designed to compare different suture materials and wound closure techniques in patients undergoing primary or aseptic revision total hip and knee arthroplasty. Participants will be randomly assigned in a 1:1 ratio to one of two wound closure strategies differing in both suture material and closure technique following total hip or knee arthroplasty. The study aims to determine their effects on wound healing, functional outcomes, and postoperative complications.

A minimum of 90 adult patients will be enrolled. Eligible patients will be randomized into two groups according to the wound closure material and technique used. All surgical procedures will be performed by the same surgical team following standardized perioperative protocols in order to minimize confounding variables.

Preoperative demographic data will be recorded. Intraoperative variables including operative time and intraoperative blood loss will be documented. Postoperative assessments will include wound drainage duration, signs of local inflammation, wound dehiscence, surgical site infection, bleeding complications, and cosmetic evaluation. Functional outcomes will be assessed using validated hip and knee scoring systems where applicable.

Patients will be followed for 90 days postoperatively. All data will be recorded in a secure database and analyzed using appropriate statistical methods. Continuous variables will be assessed for normal distribution and analyzed using parametric or non-parametric tests as appropriate. Categorical variables will be analyzed using Chi-square or Fisher's exact test. Multivariate logistic regression analysis will be performed to identify independent predictors of wound-related complications. A p-value \< 0.05 will be considered statistically significant.

The findings of this study are expected to contribute to the optimization of wound closure strategies in lower extremity arthroplasty and improve postoperative outcomes.

03

Conditions studied

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip

Keywords

  • Total Knee Arthroplasty
  • Total Hip Arthroplasty
  • Wound Closure
  • Barbed Suture
  • Surgical Site Infection
  • Wound Healing
  • Arthroplasty
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 30 years
  • Patients undergoing primary total hip arthroplasty or total knee arthroplasty
  • Patients undergoing aseptic revision total hip or knee arthroplasty
  • Surgery performed by the same surgical team
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Age \< 30 years
  • Patients receiving therapy
  • Patients with complicated diabetes mellitus
  • Chronic venous insufficiency
  • Peripheral arterial disease
  • Arthroplasty performed due to
  • Active or previous surgical site infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Barbed Suture Group

    Patients undergoing total hip or knee arthroplasty in whom wound closure is performed using barbed suture material and continuous closure technique.

    Procedure: Barbed Suture Wound Closure

  • Active comparator
    Conventional Suture Group

    Patients undergoing total hip or knee arthroplasty in whom wound closure is performed using conventional suture material and standard closure technique.

    Procedure: Conventional Suture Wound Closure

Interventions

  • ProcedureBarbed Suture Wound Closure

    Wound closure using barbed suture material with continuous technique following total hip or knee arthroplasty.

  • ProcedureConventional Suture Wound Closure

    Wound closure using conventional suture material with interrupted or standard closure technique following total hip or knee arthroplasty.

06

What researchers measure

Primary outcomes

  1. Incidence of wound-related complications within 90 days postoperatively

    Wound-related complications include prolonged wound drainage, wound dehiscence, surgical site infection, and local inflammatory findings occurring within 90 days following total hip or knee arthroplasty.

    Time frame: Within 90 days after surgery

Secondary outcomes

  1. Operative Time

    Duration of surgery measured in minutes from skin incision to wound closure.

    Time frame: Intraoperative (Day of surgery)

  2. Intraoperative Blood Loss

    Estimated blood loss measured in milliliters during surgery.

    Time frame: Intraoperative (Day of surgery)

  3. Duration of Postoperative Wound Drainage

    Number of days with visible wound drainage after surgery.

    Time frame: Within 90 days after surgery

  4. Surgical Site Infection Rate

    Incidence of superficial or deep surgical site infection diagnosed according to clinical criteria within 90 days postoperatively.

    Time frame: Within 90 days after surgery

  5. Wound Dehiscence

    Incidence of partial or complete wound separation within 90 days postoperatively.

    Time frame: Within 90 days after surgery

  6. Functional Outcome Score

    Functional outcomes will be assessed using the Harris Hip Score (HHS) (range 0-100, with 100 indicating best possible function; higher scores indicate better clinical outcomes) for patients undergoing total hip arthroplasty, and the Knee Society Score (KSS) (range 0-100, with 100 indicating best possible function; higher scores indicate better clinical outcomes) for patients undergoing total knee arthroplasty.

    Time frame: Preoperatively and at 3 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect patient confidentiality and comply with institutional policies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 9 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439575
Lead sponsor
Bahattin Kemah
Responsible party
Bahattin Kemah (Orthopedic Surgeon, Department of Orthopedics, Umraniye Education and Research Hospital) — Sponsor-investigator
First posted
Feb 27, 2026
Start date
Nov 1, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Bahattin Kemah, MD
Contact
bahattinkemah.md@gmail.com
+905337198121
Bahattin Kemah, MD
principal investigator · Umraniye Education and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion